ArticleOncogene2017
p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Abstract read
In one paragraph
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.BMJ open · 2024Pooled it
- SKP2 in Cancer: From Molecular Regulation to Therapeutic Vulnerabilities and Translational Perspectives.Drug design, development and therapy · 2026Review
- Harnessing organoid technology in urological cancer: advances and applications in urinary system tumors.World journal of surgical oncology · 2025Review
- Distinct outcomes from targeted perturbations of the multi-subunit SCFCommunications biology · 2025Article
- Ceftazidime is a potential drug to inhibit cell proliferation by increasing cellular p27.The Journal of antibiotics · 2024Article
- O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.Oncogene · 2024Article
- Targeted inhibition of SCFOncogene · 2024Article
- Effect of ubiquitin protease system on DNA damage response in prostate cancer (Review).Experimental and therapeutic medicine · 2024Review
- Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review.Frontiers in pharmacology · 2023Review
- Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.British journal of cancer · 2022Review
- CHPF promotes gastric cancer tumorigenesis through the activation of E2F1.Cell death & disease · 2021Article
- The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.Scientific reports · 2021Article
- The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.Annals of the New York Academy of Sciences · 2021Article
- Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma.Translational oncology · 2020Article
- Targeted Inhibition of the E3 Ligase SCFCancer research · 2020Article
- Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.Molecular medicine reports · 2019Article
- Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.Disease markers · 2019Article
- MicroRNA-940 inhibits glioma cells proliferation and cell cycle progression by targeting CKS1.American journal of translational research · 2019Article
- Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.Oncogene · 2018Article
- Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.MedChemComm · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
H ZhaoDepartments of Developmental and Molecular Biology, and Ophthalmology and Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Z LuDepartments of Developmental and Molecular Biology, and Ophthalmology and Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.
F BauzonDepartments of Developmental and Molecular Biology, and Ophthalmology and Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.
H FuDepartments of Developmental and Molecular Biology, and Ophthalmology and Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.
J CuiDepartments of Developmental and Molecular Biology, and Ophthalmology and Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.
J LockerDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
L ZhuDepartments of Developmental and Molecular Biology, and Ophthalmology and Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Albert Einstein College of Medicine · USUniversity of Pittsburgh · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2MSpecial Animal CoreP30DK041296 · NIDDK · YESHIVA UNIVERSITY · PI GUPTA, SANJEEV · 1989 to 2018
$22.9MDissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesisR01CA201458 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SCHWARTZ, EDWARD L, ZHAO, HONGLING · 2016 to 2020
$1.9MDIFFERENTIATION OF HEPATIC STEM CELLSR01DK061153 · NIDDK · YESHIVA UNIVERSITY · PI ROGLER, LESLIE E · 2001 to 2005
$1.9MRole of Skp2-cyclin A Interaction in Normal Physiology and CancerR01CA131421 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ZHU, LIANG · 2009 to 2013
$1.5MSkp2 in androgen-dependent proliferation of prostate cancer cellsR01CA127901 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ZHU, LIANG · 2009 to 2012
$1.2MNCI NIH HHS P30 CA013330NCI NIH HHS R01 CA127901NCI NIH HHS R01 CA131421NCI NIH HHS R01 CA201458NIDDK NIH HHS P30 DK041296NIDDK NIH HHS R01 DK061153
Abstract
SCF
Indexed as
AnimalsApoptosisCDC2-CDC28 KinasesCell Line, TumorCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p27Disease ProgressionE2F1 Transcription FactorGene Knock-In TechniquesHumansMaleMiceMice, KnockoutMice, TransgenicNeoplasm StagingProstateCDC2-CDC28 KinasesCKS1B protein, humanCyclin-Dependent Kinase Inhibitor p27E2F1 Transcription FactorRetinoblastoma ProteinS-Phase Kinase-Associated ProteinsTumor Protein p73Tumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.